MetabolAid, Eriomin, Chromium Picolinate, Filling Agent (Rice Starch), Anti-Caking Agent (Magnesium salts of fatty acids), Glazing Agent (Capsule (Hydroxypropyl Methylcellulose))
These findings point towards a broader therapeutic application of semaglutide, beyond its known benefits for metabolic health
The dataset connects claims, labs and EHR, including physician notes to analyse: Who meets drug label or payer criteria based on actual BMI and comorbidities How titration and dosing progress in real-world care What metabolic outcomes patients achieve over time Which safety signals, such as liver or renal changes, emerge across populations Why patients discontinue or switch treatments, as documented in notes See real-world GLP-1 evidence in action Register for our webinar where we dive deeper into GLP-1 real-world evidence
These definitive findings underscore L-carnitine's vital, irreplaceable role in supporting heart muscle energy, which is a critical consideration for patients desperately trying to manage the severe cardiovascular symptoms of dysautonomia and POTS